Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19224 ↗Kurz gefasst
Leitlinie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Mark Drayson und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology Service, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cancer Research UK, Myeloma UK.
Abstract (Originalsprache)
Treatment advances have greatly improved survival, but myeloma is among the worst of all cancers for delayed diagnosis, causing serious morbidities and early deaths. This delay is largely because the symptom profile of myeloma has very low specificity, and in primary care, myeloma is rare. However, initiating the journey to diagnosis simply requires considering myeloma and sending blood to test for monoclonal immunoglobulin. Laboratory tests reliably detect monoclonal immunoglobulin, which is present in 99% of myeloma cases, so why do health care systems have such a problem with delayed diagnosis? The Myeloma UK early diagnosis programme has brought together diverse expertise to investigate this problem, and this article was prepared by the programme's working group for laboratory best practice. It reviews evidence for test requesting, analysis and reporting, for which there is large variation in practice across the United Kingdom. It presents a ‘GP Myeloma diagnostic tool’ and how it can be integrated into laboratory practice alongside a laboratory best practice tool. It proposes improved requesting and integration with haematology services for reporting and interpretation. Here the laboratory has a central role in creating efficient and cost‐effective pathways for appropriate and timely bone marrow examination for myeloma diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Immunology Service, University of Birmingham, Birmingham, UK.
- Myeloma UK, Edinburgh, UK.
- UK NEQAS Immunology, Immunochemistry & Allergy, Sheffield Teaching Hospitals, Sheffield, UK.
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
- Protein Reference Unit, South West London Pathology, St Georges Hospital, London, UK.
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
ORCID-Profile: Mark Drayson, Guy Pratt
Förderung
- Cancer Research UK
- Myeloma UK
Zitieren
APA
Drayson, M., Jennis, T., Laketic-Ljubojevic, I., Patel, D., Pratt, G., Renwick, S., Richter, A., Wheeler, R., Sheldon, J., Sadler, R., Stapleton, M., Willis, F., Whiston, M., & for Myeloma UK working group for laboratory best practice (2024). Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services. British Journal of Haematology. https://doi.org/10.1111/bjh.19224
Vancouver
Drayson M, Jennis T, Laketic-Ljubojevic I, Patel D, Pratt G, Renwick S, et al. Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services. British Journal of Haematology. 2024. doi:10.1111/bjh.19224
BibTeX
@article{Drayson2024,
author = {Drayson, Mark and Jennis, Tom and Laketic-Ljubojevic, Ira and Patel, Dina and Pratt, Guy and Renwick, Suzanne and Richter, Alex and Wheeler, Rachel and Sheldon, Joanna and Sadler, Ross and Stapleton, Mary and Willis, Fenella and Whiston, Mairi and for Myeloma UK working group for laboratory best practice, for Myeloma UK working group for laboratory best practice},
title = {Laboratory practice is central to earlier myeloma diagnosis: Utilizing a primary care diagnostic tool and laboratory guidelines integrated into haematology services},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19224}
}
EUVIMED